Frankfurt
13.01.25
09:15 Uhr
4,720 Euro
+0,020
+0,43 %
+0,43 %
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 4,820 | 5,100 | 17:32 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.01. | ASCENTAGE-B (06855): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 02.01. | ASCENTAGE-B (06855): (1) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) CHANGE IN COMPOSITION OF BOARD COMMITTEES | 1 | HKEx | ||
| 30.12.24 | Takeda-backed Ascentage Pharma files for $100M IPO | 38 | Seeking Alpha | ||
| 28.12.24 | Cancer and HBV biotech Ascentage Pharma files for a $100 million US IPO | 1 | Renaissance Capital | ||
| 27.12.24 | ASCENTAGE PHARMA GROUP INTERNATIONAL - F-1, Registration statement for certain foreign private issuers | - | SEC Filings | ||
| 24.12.24 | BRIEF: Ascentage Pharma gets Chinese regulatory nod for U.S. listing | 2 | Bamboo Works | ||
| 28.11.24 | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF OLVEREMBATINIB INCLUDED INTO CHINA 2024 NATIONAL REIMBURSEMENT DRUG LIST | - | HKEx | ||
| 25.11.24 | ASCENTAGE-B (06855): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| ASCENTAGE PHARMA GROUP Aktie jetzt für 0€ handeln | |||||
| 25.11.24 | ASCENTAGE-B (06855): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS | - | HKEx | ||
| 22.11.24 | Ascentage Pharma: Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology | 98 | PR Newswire | ROCKVILLE, Md. and SUZHOU, China, Nov. 21, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing... ► Artikel lesen | |
| 17.11.24 | Ascentage Pharma's NDA For Bcl-2 Inhibitor Lisaftoclax Accepted With Priority Review By China's CDE | 3 | RTTNews | ||
| 06.11.24 | ASCENTAGE-B (06855): VOLUNTARY ANNOUNCEMENT - ASCENTAGE PHARMA TO PRESENT RESULTS FROM MULTIPLE CLINICAL STUDIES OF OLVEREMBATINIB, LISAFTOCLAX, APG-5918 ... | 1 | HKEx | ||
| 25.10.24 | ASCENTAGE-B (06855): SUPPLEMENTAL ANNOUNCEMENT - (1) CANCELLATION OF THE ORIGINAL GRANT OF AWARDS UNDER THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME; AND ... | 5 | HKEx | ||
| 08.10.24 | ASCENTAGE-B (06855): ASCENTAGE PHARMA RECEIVED CDE CLEARANCE FOR REGISTRATIONAL PHASE III STUDIES OF APG-2449 FOR TREATMENT OF PATIENTS WITH NSCLC | 3 | HKEx | ||
| 01.10.24 | ASCENTAGE-B (06855): INTERIM REPORT 2024 | 2 | HKEx | ||
| 02.09.24 | ASCENTAGE-B (06855): FURTHER GRANT OF AWARDS UNDER THE 2018 RSU SCHEME, THE 2021 RSU SCHEME AND THE 2022 RSU SCHEME | - | HKEx | ||
| 22.08.24 | Ascentage Pharma Announces 2024 Interim Results | 352 | PR Newswire | ROCKVILLE, Md. and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both first-in-class... ► Artikel lesen | |
| 22.08.24 | ASCENTAGE-B (06855): ANNOUNCEMENT OF UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024 | - | HKEx | ||
| 13.08.24 | Ascentage Pharma: Registrational Phase III Study of Lisaftoclax in Newly-Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome Cleared by China CDE | 125 | PR Newswire | ROCKVILLE, Md. and SUZHOU, China, Aug. 12, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing... ► Artikel lesen | |
| 09.08.24 | ASCENTAGE-B (06855): NOTICE OF BOARD MEETING | - | HKEx |
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 8,080 | -4,04 % | Evotec-Aktie heute gut behauptet: Aktienwert steigt (8,76 €) | Am deutschen Aktienmarkt liegt die Evotec-Aktie aktuell im Plus. Der jüngste Kurs betrug 8,76 Euro. Heute hat sich an der deutschen Börse die Aktie von Evotec zwischenzeitlich um 2,58 Prozent verteuert.... ► Artikel lesen | |
| CUREVAC | 3,880 | -5,96 % | dpa-AFX-Überblick: UNTERNEHMEN vom 06.01.2025 - 15.15 Uhr | ROUNDUP/US-Markt: Volkswagen-Konzern mit Licht und Schatten - BMW legt zu RESTON/HERNDON/WOODCLIFF LAKE - Der Volkswagen-Konzern hat auf dem US-Markt 2024 ein gemischtes Ergebnis eingefahren. Die... ► Artikel lesen | |
| NOVAVAX | 8,373 | -7,92 % | Novavax punktet: Impfstoffpotenzial stabilisiert Aktie | Die Aktie von Novavax konnte sich nach einem volatilen Jahr stabilisieren. Wachsende Sorgen um eine Vogelgrippe-Pandemie und das Potenzial neuer Impfstoffe rücken den Biotech-Spezialisten ins Rampenlicht.... ► Artikel lesen | |
| OCUGEN | 0,732 | -4,50 % | Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 -A Novel Modifier Gene Therapy for Retinitis Pigmentosa | 100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years100% (9/9) of treated evaluable subjects demonstrated... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,932 | -2,72 % | Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease | Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease
Varoglutamstat Phase 2 program shows highly consistent, statistically significant and... ► Artikel lesen | |
| DYNAVAX | 12,520 | +1,58 % | Dynavax Technologies: Dynavax Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Highlights | Preliminary 2024 HEPLISAV-B® net product revenue grew 26% year-over-year to approximately $268 million
Enrollment completed in Phase 1/2 shingles trial; top... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,986 | -2,89 % | PacBio Stock May Gain Following the Collaborated Launch of GutID | ||
| CARDIOL THERAPEUTICS | 1,256 | +0,80 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 22.11.2024 / 11:05 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
| EXELIXIS | 34,820 | -0,97 % | Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 | ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,436 | -5,22 % | NurExone Biologic Inc.: NurExone Biologic sichert sich Master-Zellbank | Ein wichtiger Meilenstein für die therapeutische Exosomen-Produktion
TORONTO und HAIFA, Israel, 8. Jan. 2025 -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Deutschland: J90)... ► Artikel lesen | |
| GUBRA | 88,80 | +0,68 % | AKTIONÄR-Depotwert Gubra: Novo-Nordisk-Schock verdaut - Aktie nimmt Fahrt auf | Vor Weihnachten hat der Biopharma-Riese Novo Nordisk mit seinem Adipositas-Hoffnungsträger CagriSema die hohen Markerwartungen nicht erfüllen können. Die ersten richtungsweisenden Phase-3-Studiendaten... ► Artikel lesen | |
| GERON | 2,860 | -7,74 % | GERON CORP - 8-K, Current Report | ||
| MICROBOT MEDICAL | 1,698 | -9,20 % | Microbot Medical Inc.: Microbot Medical Closes $8.6 Million Registered Direct Offering | ||
| AFFIMED | 1,080 | -6,09 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| IMMUNITYBIO | 2,440 | +3,08 % | ImmunityBio gains unique J-code for bladder cancer treatment |
ASCENTAGE PHARMA GROUP INTERNATIONAL gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,43 % bei einem Aktienkurs von 4,720 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ASCENTAGE PHARMA GROUP INTERNATIONAL finden Sie auf Wallstreet Online.
